Cell therapy Archives

News and Trends 14 Oct 2019

Mogrify Raises €15M Series A to Chase the ‘Holy Grail’ of Cell Therapy

Cambridge-based Mogrify has raised €14.5M to develop a technology that could allow scientists to transform any human cell into another cell type without the arduous process of turning them into a stem cell first. The Series A round was led by Ahren Innovation Capital, an investment firm founded by science entrepreneurs from the UK […]

October 14, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

stem cell therapy deafness rinri therapeutics

Startup Scout 11 Oct 2019

This Biotech Is Developing a Stem Cell Therapy for Deafness

Sheffield is one of the UK’s historic industrial bases. It also hosts the biotech Rinri Therapeutics, which is developing a stem cell therapy to treat deaf patients who are not eligible for cochlear implants. Mission: To develop a stem cell therapy for a rare form of deafness where the neuronal wiring underlying the auditory system […]

October 11, 2019 - 3 minutesmins - By Jonathan Smith

lightcast discovery cell therapy cambridge uk

Startup Scout 27 Sep 2019

This Biotech Can Screen CAR T-Cells Using Only Light and Microfluidics

Based in Cambridge, UK, Lightcast Discovery is developing microfluidics technology that automates cell screening experiments by using lasers. Mission: To automate cell screening experiments, such as those used when screening CAR T-cell immunotherapies. This would let companies test therapies in complex cell experiments, such as cell-to-cell interactions, which are difficult with traditional drug-screening tools. Cell […]

September 27, 2019 - 3 minutesmins - By Jonathan Smith

grunenthal mesoblast chronic low back pain

News and Trends 11 Sep 2019

Grünenthal to Pay up to €900M for Chronic Low Back Pain Cell Therapy

The German pharmaceutical company Grünenthal has licensed a donor cell therapy for chronic low back pain from the Australian biotech Mesoblast in a deal that could be worth over €900M. Under the terms of the deal, Grünenthal will gain exclusive rights to commercialize Mesoblast’s cell therapy for chronic low back pain in Europe and Latin […]

September 11, 2019 - 2 minutesmins - By Jonathan Smith

blood cancer stem cell therapy brain cancer

News and Trends 11 Sep 2019

Italian Biotech Raises €13M to Test Stem Cell Therapy for Cancer

The Italian biotech Genenta Science has raised €13.2M in a private round to fund two ongoing phase I/II trials of its stem cell therapy Temferon for blood and brain cancer. Genenta Science will use the money to fund two European phase I/II trials, which the company launched in March. One trial is testing the stem […]

September 11, 2019 - 3 minutesmins - By Jonathan Smith

gene therapy cell therapy advanced therapy 4BIO

News and Trends 9 Sep 2019

4BIO Capital Raises €45M Fund to Invest in Advanced Therapies

The London-based life sciences investor 4BIO Capital has raised €45M in the first close of a fund to nurture companies developing advanced therapies such as gene and cell therapies. This is the first closing of 4BIO’s second fund, called 4BIO Ventures II, which is expected to total €136M ($150M) by late 2020. The fund will […]

September 9, 2019 - 3 minutesmins - By Jonathan Smith

cancer cell therapy immunotherapy achilles therapeutics

News and Trends 3 Sep 2019

UK Biotech’s Personalized Immunotherapy gets €110M Series B Boost

The UK company Achilles Therapeutics has raised €110M (£100M) to test its personalized cancer cell immunotherapies in humans for the first time. The large Series B round will fund two phase I/IIa clinical trials of Achilles’ preclinical immunotherapy which are expected to start this year: one in non-small cell lung cancer and the other in […]

September 3, 2019 - 2 minutesmins - By Jonathan Smith

dendritic cell immunicum cancer immunotherapy cell therapy

News and Trends 29 Aug 2019

Off-the-Shelf Kidney Cancer Immunotherapy More Than Doubles Recovery in Phase II

An off-the-shelf cancer immunotherapy developed by the Swedish biotech Immunicum has eradicated kidney tumors in 11% of treated patients compared with just 4% of patients given standard treatments in a phase II trial. Immunicum is developing a cell immunotherapy to treat metastatic renal cell carcinoma. This advanced form of kidney cancer is particularly hard to […]

August 29, 2019 - 3 minutesmins - By Jonathan Smith

celgene immatics cancer cell immunotherapy

News and Trends 28 Aug 2019

Celgene and Immatics Sign Deal Worth Over €1.35B to Develop Cancer Immunotherapies

The US company Celgene has obtained options to three cancer immunotherapy programs from the German biotech Immatics in a deal worth more than €1.35B ($1.5B). Immatics is to receive an upfront payment of €67.5M ($75M), along with up to €455M ($505M) in developmental milestones and royalties for each immunotherapy program. In each program, Immatics will […]

August 28, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 15 Aug 2019

Swiss Scientists Upgrade CRISPR to Edit Many Genes at Once

A research group at ETH Zurich, Switzerland, has made it possible to edit hundreds of genes at once with CRISPR gene editing. CRISPR gene editing has revolutionized the biotech industry by providing an easy and quick way to genetically modify organisms. So far, however, CRISPR techniques have only managed to edit a maximum of seven […]

August 15, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 12 Aug 2019

Manufacturing Delays Set Back Autolus’ CAR-T Programs by Five Months

The UK biotech Autolus’ shares have slumped as construction delays from a new manufacturing site have pushed back its CAR-T cell immunotherapy programs. Autolus is developing treatments for blood cancer that involve engineering patients’ own immune cells to kill cancer cells, known as autologous CAR-T cell immunotherapies. Earlier this year, Autolus licensed a new manufacturing […]

August 12, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 1 Jul 2019

Approval Status of Cancer Cell Therapy at Risk After Halting Phase III Trial

Following an unfavorable interim analysis, Milan-based MolMed has suspended a phase III trial of its cell therapy Zalmoxis that could threaten the conditional marketing authorization the treatment received in 2016. The halted clinical trial was evaluating the effects of Zalmoxis on patients with high-risk leukemia that have received a bone marrow transplant. The cell therapy […]

July 1, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cell therapy

Mogrify Raises €15M Series A to Chase the ‘Holy Grail’ of Cell Therapy

This Biotech Is Developing a Stem Cell Therapy for Deafness

This Biotech Can Screen CAR T-Cells Using Only Light and Microfluidics

Grünenthal to Pay up to €900M for Chronic Low Back Pain Cell Therapy

Italian Biotech Raises €13M to Test Stem Cell Therapy for Cancer

4BIO Capital Raises €45M Fund to Invest in Advanced Therapies

UK Biotech’s Personalized Immunotherapy gets €110M Series B Boost

Off-the-Shelf Kidney Cancer Immunotherapy More Than Doubles Recovery in Phase II

Celgene and Immatics Sign Deal Worth Over €1.35B to Develop Cancer Immunotherapies

Swiss Scientists Upgrade CRISPR to Edit Many Genes at Once

Manufacturing Delays Set Back Autolus’ CAR-T Programs by Five Months

Approval Status of Cancer Cell Therapy at Risk After Halting Phase III Trial

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!